You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 4, 2024

Claims for Patent: 7,674,479

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,674,479

Title:	Sustained-release bupropion and bupropion/mecamylamine tablets
Abstract:	Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.
Inventor(s):	Zerbe; Horst G. (Hudson, CA), Paiement; Nadine (Montreal, CA)
Assignee:	Intelgenx Corp. (St. Laurent, CA)
Application Number:	11/828,287
Patent Claims:	1. A sustained release pharmaceutical tablet comprising: sustained release granules consisting essentially of bupropion hydrochloride admixed with a hydroxyalkylcellulose; and an extragranular phase comprising a particulate material that provides a sustained release matrix; said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide, the granules being distributed within the extragranular phase. 2. The tablet of claim 1 further comprising sustained release mecamylamine hydrochloride granules. 3. The tablet of claim 1, wherein said extragranular phase further comprises mecamylamine hydrochloride. 4. The tablet of claim 1, wherein said hydroxyalkylcellulose is hydroxypropylcellulose. 5. The tablet of claim 1, further comprising an enteric coating. 6. A sustained release pharmaceutical tablet comprising: an uncoated sustained release granular phase comprising bupropion hydrochloride admixed with a hydroxyalkylcellulose; and an extragranular phase comprising a particulate material that provides a sustained release matrix; said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide, the uncoated granular phase being distributed within the extragranular phase. 7. The tablet of claim 6, further comprising sustained release mecamylamine hydrochloride granules. 8. The tablet of claim 6, wherein said extragranular phase further comprises mecamylamine hydrochloride. 9. The tablet of claim 6, wherein said hydroxyalkylcellulose is hydroxypropylcellulose. 10. The tablet of claim 6, further comprising an enteric coating.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.